Assessment of Risk Factors for Acquiring Colonization With Candida Auris During an Outbreak in ICU.

May 18, 2026 updated by: Dr. Daniel Leshin Carmel, Barzilai Medical Center
The study is aimed to assess the risk factors for acquiring candida auris skin colonization during an outbreak in an ICU.

Study Overview

Status

Completed

Conditions

Detailed Description

Candida auris is unique when compared to other pathogenic fungi, as it spreads in the hospital rapidly. Therefore, it can cause healthcare-associated infections and outbreaks, it is resistant to antimicrobials and disinfectants and it is persisting on human skin and in the inanimate environment. There are few works listing factors found associated with candida auris candidemia, including longer CVC days, prior antibiotics, mechanical ventilation and longer ICU stay. Most of the research for candida auris risk factor doesn't differentiate colonization and infection, or, focuses on risk factors leading from colonization to infection. The study is aimed to assess the risk factors for acquiring candida auris skin colonization during an outbreak in an ICU.

Study Type

Observational

Enrollment (Actual)

771

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Israel
      • Ashkelon, Israel
        • Barzilai Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

All patients hospitalized in ICU

Description

Inclusion Criteria:

  • hospitalization in ICU
  • Screened for candida auris

Exclusion Criteria:

  • Age <18 yeas.
  • No data.
  • No candida screen.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Non colonized
Patient not colonized with candida auris
Colonized
Patient colonized with candida auris

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Colonization with Candida auris
Time Frame: From hospitalization in ICU until 2 weeks following discharge from ICU, a maximum of 90 days.
Positive screening for candida auris, taken by nose/ armpits and groin swabs and either directly seeded on a selective medium or by positive PCR.
From hospitalization in ICU until 2 weeks following discharge from ICU, a maximum of 90 days.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Barzilai Medical Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 15, 2026

Primary Completion (Actual)

May 1, 2026

Study Completion (Actual)

May 1, 2026

Study Registration Dates

First Submitted

February 15, 2026

First Submitted That Met QC Criteria

April 15, 2026

First Posted (Actual)

April 22, 2026

Study Record Updates

Last Update Posted (Actual)

May 20, 2026

Last Update Submitted That Met QC Criteria

May 18, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • BRZ-0103-25

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Candida Auris Colonization

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bangladesh

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe